Short Versus Long Antiplatelet Therapy After TAVI

The goal of this clinical trial is to learn if reducing the duration of treatment by aspirin to 3 months (short treatment regimen) after percutaneous aortic valve replacement is as safe and efficient as the routine lifetime treatment by aspirin (standard treatment regimen). The main questions it aims to answer are: Does the reduction of the duration of aspirin reduces rates of bleeding without increasing the risk of cardiovascular events. Researchers will compare a short treatment by aspirin (3 months) to a long treatment by aspirin (12 months) after percutaneous replacement of the aortic valve. Participants will: Take aspirin for 3 months in one group or 12 months in another group Be contacted by phone or visit the clinic at 3, 4, 6, 8, 10 and 12 months after hospital discharge Keep a diary of any bleeding or cardiovascular events occurring during the study period

NCT Number	NCT06518317
Lead Sponsor	University Hospital, Caen
Conditions	Transcatheter Aortic Valve Replacement
Enrollment	1,400 participants
Start Date	2024-11-21
Primary Completion	2028-11 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-26